首页 | 本学科首页   官方微博 | 高级检索  
     


Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis.
Authors:G Ju   E Labriola-Tompkins   C A Campen   W R Benjamin   J Karas   J Plocinski   D Biondi   K L Kaffka   P L Kilian   S P Eisenberg  et al.
Affiliation:Department of Molecular Genetics, Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ 07110.
Abstract:Interleukin 1 (IL-1) receptor antagonist (IL-1ra) is a naturally occurring protein that binds to the IL-1 receptor present on T cells, fibroblasts, and other cell types and acts to block IL-1-induced responses. IL-1ra is a pure antagonist and has no agonist activity in in vitro or in vivo systems. By site-specific mutagenesis, an analog of IL-1ra was created that contained a substitution of a single amino acid, Lys-145----Asp. This analog, IL-1ra K145D, exhibited partial agonist activity in the D10.G4.1 cell proliferation assay. The newly acquired agonist activity could not be neutralized by antisera to IL-1 alpha or IL-1 beta, but it could be blocked by a monoclonal antibody to the T-cell IL-1 receptor. The analog also showed agonist activity as assayed by increased prostaglandin E2 synthesis from CHO cells expressing recombinant mouse IL-1 receptor. These results with IL-1ra K145D demonstrate the importance of the region surrounding the corresponding Asp-145 residue in IL-1 beta for triggering the biological response to IL-1.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号